"Ever since Merck (Charts, Fortune 500) recalled its Vioxx painkiller medication in 2004, the FDA has been stingy about rubber stamping new drugs. CEOs aren't to blame for that - and investors know it."
So, the FDA is more stingy these days, is it? That could be a cause of more lobbying...
http://money.cnn.com/2007/10/01/news/companies/wyeth_ceo.fortune/index.htm?source=yahoo_quote
Lessons from a Big Pharma downfall
Bob Essner deserves a lot of credit for turning around Wyeth. In the end, however, the departing CEO may have been a victim of his own hype, writes Fortune's John Simons.
By John Simons, Fortune writer
October 1 2007: 4:41 PM EDT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment